Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy

Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2... Ann Surg Oncol (2017) 24:2556–2562 DOI 10.1245/s10434-017-5898-z OR IG INA L A R TIC L E – BREA S T O NC OLOG Y Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy 1 1 2 1 Oriana A. Petruolo, MD , Melissa Pilewskie, MD , Sujata Patil, PhD , Andrea V. Barrio, MD , Michelle Stempel, 1 3 1 MPH , Hannah Y. Wen, MD, PhD , and Monica Morrow, MD 1 2 Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ABSTRACT axilla, nodal pCR among cN? patients (n = 301) ranged Background. The benefit of neoadjuvant chemotherapy from 0 to 35% (p \ 0.0001) within these groups, and was (NAC) in patients with estrogen receptor-positive (ER?)/ most frequent in PR-/HP patients. human epidermal growth factor receptor 2-negative Conclusions. ER?/HER2- patients most likely to benefit (HER2-) breast cancers and in invasive lobular carcinoma from NAC are those with PR- and HP tumors. Patients (ILC) is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy

Loading next page...
 
/lp/springer_journal/standard-pathologic-features-can-be-used-to-identify-a-subset-of-W0SBd8anKI
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-017-5898-z
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2017) 24:2556–2562 DOI 10.1245/s10434-017-5898-z OR IG INA L A R TIC L E – BREA S T O NC OLOG Y Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy 1 1 2 1 Oriana A. Petruolo, MD , Melissa Pilewskie, MD , Sujata Patil, PhD , Andrea V. Barrio, MD , Michelle Stempel, 1 3 1 MPH , Hannah Y. Wen, MD, PhD , and Monica Morrow, MD 1 2 Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY ABSTRACT axilla, nodal pCR among cN? patients (n = 301) ranged Background. The benefit of neoadjuvant chemotherapy from 0 to 35% (p \ 0.0001) within these groups, and was (NAC) in patients with estrogen receptor-positive (ER?)/ most frequent in PR-/HP patients. human epidermal growth factor receptor 2-negative Conclusions. ER?/HER2- patients most likely to benefit (HER2-) breast cancers and in invasive lobular carcinoma from NAC are those with PR- and HP tumors. Patients (ILC) is

Journal

Annals of Surgical OncologySpringer Journals

Published: May 30, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off